Imfinzi improves survival in biliary tract cancer
19 January 2022 07:05 GMT Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer TOPAZ-1 is the first Phase III trial to show improved survivalwith an immunotherapy combination in this setting Combination did not increase discontinuations due to adverse events vs. chemotherapy alone Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca's Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and